Twitxy Saved

Pacific Edge

Verified account This account is verified. Learn more

@PacificEdgeLtd

A global cancer diagnostics company. We specialise in genomic testing for patients presenting with hematuria or in surveillance for recurrent urothelial cancer.
Dunedin City, New Zealand pacificedgedx.com Joined July 2010
282 Following 780 Followers 1.3K Posts

Latest posts 5

Pacific Edge Verified account @PacificEdgeLtd
#WatchNow Following the publication of a final LCD and confirmed Medicare coverage for Cxbladder Triage and Triage Plus last week, Pacific Edge CEO Dr Peter Meintjes sat down with Lel Smits from Australian investor platform The Stock Network ahead of the upcoming Bell Potter Healthcare Conference.

In the interview, Dr Meintjes discusses the significance of Medicare coverage, the clinical evidence underpinning our tests, and what the decision means for patients and physicians as Pacific Edge continues to build momentum in the US. He also looks ahead to the development and commercialisation pathway for Surveillance Plus, a next-generation Cxbladder test for patients being monitored for recurrent disease.

Watch the interview below.
TSN: The Stock Network Verified account @TheStockNet Nov 9
Pacific Edge (ASX:PEB) CEO Dr Peter Meintjes is speaking ahead of presenting at Bell Potter’s Healthcare Conference, discussing the company’s newly confirmed US Medicare coverage for its Cxbladder Triage and Triage Plus tests, its growing commercial traction in the US healthcare market and the development of its next bladder cancer test.

TSN Interview:
🇺🇸 Securing US Medicare coverage for bladder cancer testing
🔬 Expanding access to Cxbladder tests across the US healthcare market
🧬 Developing the next generation of bladder cancer testing
⚡ Watch the full interview: youtube.com/watch?v=OAzNDl…

Register for Bell Potter's Healthcare conference:
🗓 17-19 Nov 2026
👉 bellpotterevent.com.au/healthcare-202… @PacificEdgeLtd $PEB @MedicareGov @Bell_Potter
View quoted post on X
Pacific Edge Verified account @PacificEdgeLtd
Major milestone! We're pleased to announce that a final Local Coverage Determination (LCD) for urine-based biomarkers in patients with microhematuria has been published to the Medicare Coverage Database, confirming Medicare coverage for Cxbladder Triage and Triage Plus in the evaluation of intermediate risk patients.

Effective December 20, the LCD establishes hematuria evaluation as a covered Medicare benefit and provides foundational medical policy, while further strengthening Pacific Edge’s market-leading position with Triage and Triage Plus the only tests covered. Learn more: hubs.la/Q04DHZkV0
Pacific Edge Verified account @PacificEdgeLtd
News to Share! Pacific Edge today announces that the final Local Coverage Determination (LCD) for urine-based biomarkers in patients with microhematuria has been published to the Medicare Coverage Database, confirming Medicare coverage for Cxbladder Triage and Triage Plus.

Pacific Edge Chief Executive Dr Peter Meintjes said: “The final LCD is a significant milestone for Pacific Edge, Medicare patients, urologists, and the broader healthcare system. It provides clear guidance on the eligible hematuria patients for which Triage and Triage Plus should be reimbursed and recognizes the important role that validated, non-invasive urine-based biomarkers can play in helping physicians make better-informed decisions about cystoscopy.
“The LCD confirms Pacific Edge as the market leader, with only Triage and Triage Plus tests covered under the policy. This leadership is a consequence of its commitment to generating the overwhelming evidence needed to change physician behavior, medical policy, and guidelines.”

Learn more: hubs.la/Q04DwPRD0
Pacific Edge Verified account @PacificEdgeLtd
New clinical evidence: We’re pleased to confirm that the AUSSIE study has been published in BJU International.

AUSSIE – the second peer reviewed clinical validation of Triage Plus and the first in an Australian population – reproduces the performance seen in the recent DRIVE study and gives Australian clinicians and hospitals local peer-reviewed evidence supporting use of the test to help rule out urothelial cancer and defer an invasive cystoscopy and unnecessary imaging in patients with a low probability of disease.

For clinical teams outside Australia, AUSSIE provides important new evidence that Cxbladder Triage Plus performs consistently across different patient populations and health systems.

Learn more: hubs.la/Q04CqJpQ0